Trial Profile
Phase I/II Trial of STI571 (NSC 716051) in Patients With Recurrent Malignant Gliomas
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 04 Jul 2018
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Astrocytoma; Glioblastoma; Glioma; Gliosarcoma; Meningioma; Oligodendroglioma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 04 Jul 2018 New trial record